CVS Health stock fell 0.9% in pre-market trading after reporting third-quarter 2026 results that beat expectations and confirming plans to split into two separate publicly traded companies by 2028.
The company posted revenues of $108.4 billion, up 5.4% year-over-year, and adjusted EPS of $2.09, surpassing Wall Street consensus of $1.65. CVS raised full-year 2026 adjusted EPS guidance to at least $8.20 and increased its cash flow from operations target to at least $15.5 billion.
The breakup plan would separate CVS's roughly 9,000 retail pharmacies from its Aetna insurance arm and Caremark pharmacy benefit management operations. This reverses the integrated strategy that drove the company's 2018 acquisition of Aetna.
BofA Securities and Barclays both reiterated Buy ratings. However, investors appeared to shift focus to execution risk after the anticipated news triggered profit-taking, a classic "sell the news" dynamic.
Headwinds include Aetna's Medicare Advantage star ratings declining for 2027, with roughly 70% of members in four-star-or-better plans compared to 81% previously. Analysts estimate this decline could translate into hundreds of millions in lost bonuses. Ongoing 340B drug-pricing reimbursement pressure and concerns about Caremark client retention also weighed on sentiment.
The S&P 500 gained nearly 1.0%, the Dow Jones rose approximately 1.4%, and the Nasdaq advanced roughly 0.9%, indicating CVS's decline was company-specific rather than macro-driven.
Investors watching CVS should monitor execution timelines for the separation and Aetna's 2027 plan performance metrics.